CAMP4 Therapeutics vs Upstream Bio
CAMP4 Therapeutics reported revenue of $4 million in fiscal 2025, 1.2 times Upstream Bio's $3 million in fiscal 2025. CAMP4 Therapeutics' revenue grew 436.5% in its latest year, and Upstream Bio's grew 20.4%. CAMP4 Therapeutics had an operating margin of -1502.4%, against -5618.8% at Upstream Bio. Free cash flow was −$30 million at CAMP4 Therapeutics and −$133 million at Upstream Bio.
Side by side
| CAMP4 Therapeutics | Upstream Bio | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $4M | $3M |
| Revenue growth | 436.5% | 20.4% |
| Revenue growth a year, last 5 years | — | — |
| Gross margin | — | — |
| Operating margin | −1,502.4% | −5,618.8% |
| Net margin | −2,298.5% | −5,026.0% |
| Free cash flow | −$30M | −$133M |
| Free cash flow margin | −852.8% | −4,675.5% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 547.8% | 293.6% |
| Last close | $4.00 | $2.00 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $77,433, sold $2.5 million | sold $104,799 |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
CAMP4 TherapeuticsUpstream Bio
Operating margin
Percent of revenue
CAMP4 TherapeuticsUpstream Bio
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
CAMP4 TherapeuticsUpstream Bio
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the CAMP4 Therapeutics and Upstream Bio pages.